Trial · NCT01931098
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With Prior Bevacizumab Treatment | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | 3 months | 0.44 | 95% Confidence Interval 0.14 to 0.72 | proportion of participants |
| Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With Prior Bevacizumab Treatment | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | 3 months | 0.18 | 95% Confidence Interval 0.06 to 0.36 | proportion of participants |
| Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With Prior Bevacizumab Treatment | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | 6 months | 0.11 | 95% Confidence Interval 0.01 to 0.39 | proportion of participants |
| Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With Prior Bevacizumab Treatment | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | 6 months | 0 | 95% Confidence Interval 0 to 0 | proportion of participants |
| Overall Survival | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | 7.1 | 95% Confidence Interval 2.9 to 8.2 | Months | |
| Overall Survival | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | 6.3 | 95% Confidence Interval 2.8 to 9.1 | Months | |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Responders - baseline | 1.1 | Standard Deviation 0.4 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Responders - baseline | 1.9 | Standard Deviation 1.3 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Responders - Cycle 1 | 2.3 | Standard Deviation 1.4 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Responders - Cycle 2 | 0.8 | Standard Deviation 0.4 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Responders - Cycle 2 | 3.5 | Standard Deviation 2.5 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Responders - Cycle 3 | 2.9 | Standard Deviation 3.4 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Responders - Cycle 4 | 2.0 | Standard Deviation 1.7 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Responders - Cycle 5 | 1.5 | scores on a scale | |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Responders - Cycle 6 | 2.1 | Standard Deviation 2.0 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Non-Responders - baseline | 1.6 | Standard Deviation 0.7 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Non-Responders - baseline | 2.8 | Standard Deviation 2.1 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Non-Responders - Cycle 1 | 3.0 | Standard Deviation 1.9 | scores on a scale |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Non-Responders - Cycle 2 | 3.0 | scores on a scale | |
| Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Overall Responders and Non-Responders - baseline | 1.3 | Standard Deviation 0.5 | scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01931098/results